For research use only. Not for use in humans.

Cevostamab (Anti- FcRH5 / IRTA2 / CD307e)

Synonyms: FCRL5， IRTA2 Cat.No.A2746 Purity:99%

Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) is a humanized IgG1-based bispecific antibody that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. MW: 145.24 kD.

Quality Control

Cited in Nature Medicine for its top-tier quality
SDS
Datasheet

Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Mechanism of Action

Description	Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) is a humanized IgG1-based bispecific antibody that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. MW: 145.24 kD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/28262555/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2249888-53-5
Molecular Weight	145.24
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07629583	RECRUITING	Drug: Cevostamab\|Drug: Tocilizumab	Lupus Erythematosus, Systemic	Genentech, Inc.	2026-10-31	PHASE1
NCT04910568	RECRUITING	Drug: Cevostamab\|Drug: Tocilizumab\|Drug: Pomalidomide\|Drug:	Multiple Myeloma	Genentech, Inc.	2021-07-26	PHASE1
NCT06934044	ACTIVE_NOT_RECRUITING	Drug: Cevostamab\|Drug: Tocilizumab	Multiple Myeloma	Hoffmann-La Roche	2025-05-13	PHASE1
NCT07555938	RECRUITING	Drug: Cevostamab\|Drug: Pomalidomide\|Drug: Dexamethasone\|Drug	Multiple Myeloma	Hoffmann-La Roche	2026-06-23	PHASE3
NCT05583617	RECRUITING	Drug: Cevostamab\|Drug: Lenalidomide\|Drug: Tocilizumab\|Drug:	Multiple Myeloma	Hoffmann-La Roche	2023-11-14	PHASE1; PHASE2
NCT05137054	RECRUITING	Drug: Linvoseltamab\|Drug: Daratumumab\|Drug: Carfilzomib\|Drug	Multiple Myeloma	Regeneron Pharmaceuticals	2022-08-17	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-07)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.